Bio-Path Holdings Inc (BPTH)

Bio-Path Holdings, Inc. to Post Q2 2024 Earnings of ($2.06) Per Share, Roth Capital Forecasts (NASDAQ:BPTH) - Defense World

Defense World

Bio-Path Holdings, Inc. (NASDAQ:BPTH) Q1 2024 Earnings Call Transcript - Insider Monkey

Insider Monkey

Antisense Oligonucleotides Market Comprehensive Analysis: Growing Strategies and Industry Segmentation Fore... - WhaTech

WhaTech

Earnings call: Bio-Path Holdings reports promising Q1 2024 results - Investing.com

Investing.com

Bio-Path: Q1 Earnings Snapshot - Houston Chronicle

Houston Chronicle

Bio-Path Holdings Reports First Quarter 2024 Financial Results - ForexTV.com

ForexTV.com

Bio-Path Holdings Reports First Quarter 2024 Financial Results

GlobeNewswire Inc.

Tesla, Amazon, Microsoft, and other tech giants are spending millions in DC. Here's who is spending the most. - Yahoo News UK

Yahoo News UK

Bio-Path (BPTH) to Release Quarterly Earnings on Wednesday - Defense World

Defense World

Bio-Path Holdings to Announce First Quarter 2024 Financial Results on May 15, 2024 - ForexTV.com

ForexTV.com

Bio-Path Holdings to Announce First Quarter 2024 Financial Results on May 15, 2024

GlobeNewswire Inc.

Bio-Path Holdings to Announce First Quarter 2024 Financial Results on May 15, 2024 - Investing.com South Africa

Investing.com South Africa

Jumia is back, growing total sales and orders in Q1 2024 - Yahoo Singapore News

Yahoo Singapore News

Bio-Path (NASDAQ:BPTH) Research Coverage Started at StockNews.com - Defense World

Defense World

Cyclacel Pharmaceuticals (NASDAQ: CYCC) Sees Significant Stock Volatility Amid New Financing Deal - BP Journal

BP Journal

GeneDx Holdings Corp. (WGS) Bolsters Financial and Strategic Position in 2024 - BP Journal

BP Journal

Cutaneous T-Cell Lymphoma (CTCL) Market Size was USD 520 million in 2023, estimates DelveInsight | 4SC, Bio ... - Barchart

Barchart

Why Vaxxinity Shares Are Trading Lower By Around 55%? Here Are Other Stocks Moving In Monday's Mid-Day Se - Benzinga

Benzinga

Bio-Path Holdings, Inc. Announces Closing of $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

GlobeNewswire Inc.

Bio-Path (BPTH) Rises on Upbeat Updates From Blood Cancer Study

Zacks Investment Research

Why Wang & Lee Group Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket - Adaptive Bio - Benzinga

Benzinga

Bio-Path Holdings, Inc. Announces $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

GlobeNewswire Inc.

Dow Surges Over 100 Points; D.R. Horton Posts Upbeat Earnings

Benzinga

Netflix Adds 9.33 Million Subscribers in Q1, Blowing Past Estimates to Reach Nearly 270 Million Total - Yahoo Movies Canada

Yahoo Movies Canada

Bio-Path Holdings Expands Global Patent Portfolio

GlobeNewswire Inc.

Bio-Path Holdings shares sink 6% after deal for at-the-market offering - MarketWatch

MarketWatch

Bio-Path Holdings Provides 2024 Clinical and Operational Update

GlobeNewswire Inc.

Bio-Path Holdings Announces 2024 Clinical and Operational Progress - TipRanks.com - TipRanks

TipRanks

Wall Street Bulls Eye a 290% Upside on Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) Amidst ... - BP Journal

BP Journal

Mesoblast's (NASDAQ: MESO) Breakthrough: A New Horizon in Pediatric Treatment Sparks Investor Excitement" - BP Journal

BP Journal

Merck Secures FDA Approval for Winrevair, Revolutionizing Treatment for Pulmonary Arterial Hypertension - BP Journal

BP Journal

Bio-Path Holdings faces Nasdaq noncompliance issue - Investing.com India

Investing.com India

Bio-Path Holdings, Inc. (NASDAQ:BPTH) Q4 2023 Earnings Call Transcript - Yahoo Finance

Yahoo Finance

Bio-Path Holdings Reports Full Year 2023 Financial Results

GlobeNewswire Inc.

Follicular Lymphoma Market to Witness Upsurge in Growth by 2032, Predicts DelveInsight | Key Companies - AbbVie ... - GlobeNewswire

GlobeNewswire

Bio-Path Holdings Announces Consolidating Reverse Stock Split - TipRanks.com - TipRanks

TipRanks

Bio-Path Holdings Announces 1-for-20 Reverse Stock Split

GlobeNewswire Inc.

Bio-Path Holdings Approves Reverse Stock Split Vote - TipRanks.com - TipRanks

TipRanks

Bio-Path Holdings Announces Completion of First Dose Cohort in Phase 1 Clinical Trial Evaluating BP1002 to Treat Refractory/Relapsed Lymphoma and Refractory/Relapsed Chronic Lymphocytic Leukemia Patients

GlobeNewswire Inc.

Antisense Oligonucleotides Industry Poised to Reach US$ 5519.6 Million by 2033-FMI Projection - PharmiWeb.com

PharmiWeb.com

Bio-Path Holdings Successfully Completes First Dose Cohort of Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia

GlobeNewswire Inc.

Why UP Fintech Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket

Benzinga

Global Small Interfering Rna Sirna Therapeutics Market Future Forecast Analysis Report And Growing Demand 2029 - openPR

openPR

What's Going On With Bio-Path Holdings Stock? - Bio-Path Hldgs (NASDAQ:BPTH) - Benzinga

Benzinga

Marginal Zone Lymphoma Market Size Expected to Demonstrate Optimal Growth in the 7MM During the Study Period ... - GlobeNewswire

GlobeNewswire

Biotech Stocks Take Centerstage as Markets Turn Red (COEP,AMLX, BMRN, EXEL, HALO, INVA, MDXG, INCY, JAZZ ... - BP Journal

BP Journal

Bio-Path Holdings, Inc.'s (NASDAQ:BPTH) Profit Outlook - Yahoo Finance

Yahoo Finance

Prexigebersen–Based Therapy Induces High CR/CRi Rates in Newly Diagnosed, Relapsed/Refractory AML - OncLive

OncLive

Why Is Bio-Path (BPTH) Stock Down 12% Today? - InvestorPlace

InvestorPlace

Bio-Path Holdings Provides Clinical and Operational Update - citybiz

citybiz